173 related articles for article (PubMed ID: 9554595)
1. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Tran HT; Blumenschein GR; Lu C; Meyers CA; Papadimitrakopoulou V; Fossella FV; Zinner R; Madden T; Smythe LG; Puduvalli VK; Munden R; Truong M; Herbst RS
Cancer Chemother Pharmacol; 2004 Oct; 54(4):308-14. PubMed ID: 15184994
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Kakeji Y; Teicher BA
Invest New Drugs; 1997; 15(1):39-48. PubMed ID: 9195288
[TBL] [Abstract][Full Text] [Related]
6. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
7. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
Teicher BA; Holden SA; Ara G; Korbut T; Menon K
Cancer Chemother Pharmacol; 1996; 38(2):169-77. PubMed ID: 8616908
[TBL] [Abstract][Full Text] [Related]
8. Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo.
Teicher BA; Wong JS; Takeuchi H; Gravelin LM; Ara G; Buxton D
Cancer Chemother Pharmacol; 1998; 42(1):24-30. PubMed ID: 9619754
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Herbst RS; Madden TL; Tran HT; Blumenschein GR; Meyers CA; Seabrooke LF; Khuri FR; Puduvalli VK; Allgood V; Fritsche HA; Hinton L; Newman RA; Crane EA; Fossella FV; Dordal M; Goodin T; Hong WK
J Clin Oncol; 2002 Nov; 20(22):4440-7. PubMed ID: 12431966
[TBL] [Abstract][Full Text] [Related]
10. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.
Teicher BA; Holden SA; Ara G; Sotomayor EA; Huang ZD; Chen YN; Brem H
Int J Cancer; 1994 Jun; 57(6):920-5. PubMed ID: 7515861
[TBL] [Abstract][Full Text] [Related]
12. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
Teicher BA; Ara G; Herbst R; Takeuchi H; Keyes S; Northey D
In Vivo; 1997; 11(4):301-11. PubMed ID: 9292296
[TBL] [Abstract][Full Text] [Related]
13. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
14. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Kato T; Sato K; Kakinuma H; Matsuda Y
Cancer Res; 1994 Oct; 54(19):5143-7. PubMed ID: 7522956
[TBL] [Abstract][Full Text] [Related]
15. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
16. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
[TBL] [Abstract][Full Text] [Related]
17. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
18. Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice.
Dabrowska-Iwanicka A; Olszewska D; Jalili A; Makowski M; Grzela T; Marczak M; Hoser G; Giermasz A; Golab J; Jakóbisiak M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):433-42. PubMed ID: 12200600
[TBL] [Abstract][Full Text] [Related]
19. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z
Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
